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Abstract
Background: Informed consent as stipulated in regulatory human research guidelines requires that a volunteer is
well-informed about what will happen to them in a trial. However researchers are faced with a challenge of how to
ensure that a volunteer agreeing to take part in a clinical trial is truly informed. We conducted a qualitative study
among volunteers taking part in two HIV clinical trials in Uganda to find out how they defined informed consent
and their perceptions of the trial procedures, study information and interactions with the research team.
Methods: Between January and December 2012, 23 volunteers who had been in the two trials for over 6 months,
consented to be interviewed about their experience in the trial three times over a period of nine months. They also
took part in focus group discussions. Themes informed by study research questions and emerging findings were
used for content analysis.
Results: Volunteers defined the informed consent process in terms of their individual welfare. Only two of the
volunteers reported having referred during the trial to the participant information sheets given at the start of the
trial. Volunteers remembered the information they had been given at the start of the trial on procedures that
involved drawing blood and urine samples but not information about study design and randomisation. Volunteers
said that they had understood the purpose of the trial. They said that signing a consent form showed that they
had consented to take part in the trial but they also described it as being done to protect the researcher in case a
volunteer later experienced side effects.
Conclusion: Volunteers pay more attention during the consent process to procedures requiring biological tests
than to study design issues. Trust built between volunteers and the research team could enhance the successful
conduct of clinical trials by allowing for informal discussions to identify and review volunteers’ perceptions. These
results point to the need for researchers to view informed consent as a process rather than an event.
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Background
Obtaining informed consent is required for all HIV clin-
ical trials, in common with clinical trials worldwide, to
ensure that volunteers who take part in the trial are well
informed and are not coerced to join a trial [1–6]. In-
formed consent refers to rules that should guide health
practitioners and researchers about how they interact with
their patients or research subjects to enable truly voluntary
participation [7, 8]. If they deviate from these rules, they
are likely to face a penalty, particularly if such deviation af-
fects the autonomy of a patient or research subject [9].
Judges at the Nuremberg tribunal enacted guidelines to
provide standard laws on the conduct of human experi-
mentation. These guidelines were needed because of the
neglect by physicians and scientists of ethical conduct, in-
cluding the principle of informed consent. These guide-
lines have since been subsequently revised and updated by
medical associations and researchers [10].
Informed consent is fundamental to conducting re-
search, as a principle in research ethics which enshrines
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the importance of respecting research subjects as au-
tonomous and protecting their wellbeing [11–13]. Today
the need to involve participants in research which is not
necessarily therapeutic has increased the requirement to
view informed consent as involving more than one inter-
action between the researcher and the research volunteer.
In other words, to look at consent as more than a one-
time event because the process involves a multiplicity of
interactions between the key actors involved [14–17].
Informed consent, as an ethical principle used in con-
ducting research with human subjects, has two main
underlying ethics theories; the deontology theory and
consequentialist theory. The deontology theory of ethics
is concerned with protecting a person’s dignity and abil-
ity to self-regulate [17]. According to this theory a re-
searcher must never use a volunteer to meet his/her
(researcher’s) own ends unless the volunteer benefits
from participating. The consequentialists on the other
hand hold that ‘the rightness or wrongness of an act is
dependent on the consequences of the act’ [14:19]. Our
research, reported in this paper, incorporates more of
the deontological theory,where the emphasis is volunteer
participation in research where a person’s dignity is
respected and he or she can make decisions during the
course of the informed consent process.
Research experience has demonstrated that an on-
going dialogue between researchers and research sub-
jects, giving the latter time to reflect and ask questions
and to consult family members or others that they trust,
can enhance the informed consent process [18, 19].
Many studies, including those investigating participants’
comprehension of the information provided to them,
have focused on understanding the issue of informed
consent from different research volunteers and patients
of what their perceptions were. Valley et al. [20], studied
women who took part in a microbicide study in Mwanza
and reported that the women were able to recall the key
information about the study. However, whether their
choice to participate in a trial was based on sound under-
standing of the benefits and risks of the trial or was a re-
sult of other factors such as trust, altruism and individual
priorities was not clear. Smith et al., [21] and Behrendt et
al., [22] have also assessed patients’ understanding of the
informed consent process and note that patients’ under-
standing is less developed than what the physicians ex-
pected, especially about aspects of research design such as
randomisation and procedures of randomised controlled
trials. There has been other research that has looked at
possible ways of sharing information between researchers,
professional health staff and participants in ways that clar-
ify what taking part in a study involves [23] or investigated
the best tools for assessing participants’ comprehension of
study information [3, 24, 25]. Mueller [26], an anthropolo-
gist who conducted an ethnographic study on the in-
formed consent process and HIV clinical trials among
people with HIV, emphasises the contingencies and uncer-
tainties that volunteers and even researchers experience
when conducting clinical trials. Other studies have exam-
ined the challenges that researchers in clinical trials may
face in sharing information, such as differences in under-
standing or power between members of the public and re-
searchers [27–31].
A systematic review of 21 studies on how informed con-
sent was defined and measured in African research set-
tings reported that comprehension is often poor among
such study participants and this means that there is a need
to develop a definition for informed consent which can be
applied better in low literacy settings in Africa [32].
Table 1 Comparison of the volunteer responses in the two case studies
Findings Trial One responses Trial Two responses
Perceptions of trial objectives Investigating how the body would react to the study
vaccines and whether it would cause harm
What would happen to their health if they stopped
taking septrin
Side effects reported Only 3 of 13 reported side effects which were: a swollen
hand, dizzy feeling on first day of vaccination, heart
palpitation but not related to high blood pressure
Only one volunteer reported that she became
frequently sick since joining the trial
Reasons for joining the trial Hope to protect from HIV Hope to get improved quality of life, help others in
future to take less drugs
Reasons for continuing in trial Avoid catching HIV which information is reinforced by
the research team at the scheduled follow up visits
It is a strategy to cope with HIV
Why a volunteer would drop out
of the trial
Loss of interest, no time to attend follow-up visits,
difficult with finding money to travel to research clinic
Failure to get money to travel for clinic visit,
discouragement from other members in the
community
aWho was involved in decision
making
The female volunteers had to inform and sometimes
seek permission from spouses. A few female volunteers
made their own decisions. The male volunteers only
make their own decisions and informed spouses but were
not obliged to.
Both male and female volunteers made their own
decisions and usually they would not share with
their partners
aTrial One procedures required that a sexual partner was known and also tested for HIV; Trial Two volunteers were not obliged to bring their partners to the research
clinic for HIV testing
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Researchers have argued that it is important to balance
the international standards of good practice with
responding to the situation in a given local context
where research is being conducted [33]. The various
studies conducted reflect the need to hear the voice of
the research volunteers on their views and experiences
when they take part in clinical trials.
The HIV-epidemic continues to pose a health threat to
many people in Africa and elsewhere [34–36]. As a re-
sult, clinical trials to test treatments and prevention ap-
proaches continue to be required, for which volunteers
need to be recruited and retained. Researchers have
identified challenges they faced while conducting long-
term clinical trials in Uganda which included high preg-
nancy rates among volunteers during trials coupled with
high dropout rates, some due to pregnancy and others
due to loss to follow-up [37–39].
Given that volunteers must understand what they are
being asked to do in a trial and what the trial is for, it is
important to study how effective informed consent pro-
cesses may be in conveying this trial information, par-
ticularly in settings where education and literacy levels
may be very varied, or the power differences between
the researcher and researched are large. Literacy levels n
Uganda were still relatively low (at 68.9 %) in 2011, the
majority of the population was living below the poverty
line (estimated at 84.9 %), the distribution of health facil-
ities also varies between urban areas and rural areas. Al-
though there are 10 referral hospitals in the country [40,
41]. The proportion of the population living within 5
kms of a health facility was 72 % in 2010, their access to
health care facilities further limited by poor infrastruc-
ture, lack of medicines and other health supplies, short-
age of human resources in the public sector, low salaries,
and lack of accommodation at health facilities. In
addition, the budget for medicines does not match the
growing needs of the population [42].
In this paper we examine the process of obtaining in-
formed consent reported by volunteers taking part in
two HIV clinical trials in Uganda, considering volun-
teers’ views on the specific act of signing consent forms
and the lessons these offer about the values, beliefs, gen-
der differentials, power dynamics and decision-making
patterns during the informed consent process.
The term 'informed consent' refers to giving all rele-
vant information about what is involved in conducting
and taking part in an HIV clinical trial, and ensuring that
the person receiving this information has the capacity to
make a decision and voluntarily consents to take part
when they are satisfied that they have understood the in-
formation [19, 43, 44].
The 'informed consent process' in this paper refers to all
elements of the process of providing informed consent,
which will include mobilising the initial recruitment of
volunteers, providing them with information about the
study and what will happen to them if they take part, a re-
view by an ethics committee of the informed consent doc-
uments and procedures and the signing of documents by
a member of the research team with each research volun-
teer. It is important to note that this process also includes
the various interactions that take place between the key
actors over the course of a clinical trial and what their ex-
periences were within the trial. Gaining informed consent
is not only the moment of securing a signature; it requires
an investment of the researcher and volunteer's time [23]
including information sharing sessions long enough to en-
sure the volunteer understands what is to happen to them
and what they are being asked to do.
Informed consent is fundamental to the ethical conduct
of research [45], emphasising the importance of respecting
the autonomy of research subjects and protecting their
wellbeing [11–13] and must therefore be documented to
be evidenced.
In the research presented in this paper we adopted the
‘process model’ of informed consent seen as a continu-
ous exchange of information throughout the course of
the health practitioner/researcher-patient relationship
rather than an ‘event model’, which focuses on the short
interaction involved in formal consent-giving so as to
examine what happens over time in the context of these
clinical trials [14]. The model sees decisions made in the
health practitioner/researcher-patient interaction as con-
tinuous in all of the interactions that occur for the dur-
ation of the study [14, 15]. The process model allows for
successive instructive exchanges of information between
the health practitioner/researcher and the patient/volun-
teer offering multiple occasions for discussing the treat-
ment or the research information. The patient/research
volunteer and health practitioner/researcher will both
ask questions and give answers during the informed
consent process. This model assumes that the volunteer
can make individual decisions during the interaction,
opening for discussion the values, beliefs, gender differ-
entials and power dynamics and decision making pat-
terns of both parties. This gives greater transparency to
decision-making and the roles of the researcher/phys-
ician and the volunteer/patient [46, 47].
The meaning and interpretation of the informed con-
sent process for all actors needs to be understood in
context to adequately capture the social and practical
implications of the current rigorous formal process,
which is guided by national and international research
ethics guidelines [48–50].
Methods
Study design
This was a a qualitative study which involved a sub-
sample of volunteers from two HIV clinical trials which
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are the cases in this paper [51, 52]. The volunteers for
the qualitative study were purposively selected [53, 54].
The study explored the implementation of the informed
consent process in two different HIV clinical trials in re-
lation to how the informed consent process was con-
structed and interpreted and what was meaningful to
each group of actors, including the trial volunteers [55,
56]. These two case studies (Trial One and Trial Two)
were selected because they were both HIV clinical trials
conducted by the same research organisation, going
through similar ethical preparations before they were
conducted. The two different trials facilitated a compari-
son since they were conducted in two different sites
precluding any possible contamination between the vol-
unteers. The analysis aimed to include participants’ per-
ceptions and experiences on all aspects of the informed
consent process and the factors that influence it in the
longer term not just focusing on the single event of sign-
ing a consent form.
Study area
The research was situated at two Medical Research
Council/Uganda Virus Research Institute (MRC/UVRI)
Uganda Research Unit on AIDS sites. Both case-study
sites were in the central region of Uganda but drew on
different types of communities. Most of the population
of the Trial One site were involved in small-scale farm-
ing producing a few cash crops like maize and coffee.
The Trial Two site was a semi-urban area near the
shores of Lake Victoria where the population was mainly
involved in fishing and selling fish, food businesses and
running small kiosks. A few were farmers. Both study
areas were affected by the HIV-epidemic.
The targeted volunteers in these trials differed in that
in Trial One they were HIV-negative, and in Trial Two
they were persons living with HIV but already prescribed
Anti-Retroviral medications (ARVs) for at least six
months.
The two clinical trials studied
Trial One was a phase I double-blind placebo-controlled
trial to evaluate safety and immunogenicity of the ex-
perimental vaccine drug F4co-adjuvanted with AS01B or
AS01E and administered with the experimental vaccine
Ad35- GRIN. The volunteers in the trial were adults
aged 18–40 years. The follow up period of volunteers
was 16 months.
Trial Two evaluated whether long-term primary and
secondary prophylaxis with Cotrimoxazole (also known
as Septrin) can be safely discontinued among Ugandan
adults on antiretroviral therapy who have achieved sus-
tained immune restoration (measured as a confirmed in-
crease in CD4 count to 250 or more cells/mm). The trial
was a phase IV double blind randomised placebo
controlled trial. The volunteers were adults aged 18–
59 years living with HIV. Follow up period was a mini-
mum of 18 months and maximum of 36 months.
Both trials had screening and enrolling procedures.
Blood and urine samples were being collected every
three months from the volunteers.
Volunteer recruitment and sampling
Twenty three volunteers were purposively selected from
the participants in the two trials who attended for clinic
visits when recruitment for this study began. Volunteers
were selected to take part in the qualitative study if they
were found at the clinic during the time the study was
happening. The volunteers were accessed in two stages;
first they were approached by research nurses working
with the trials to briefly inform them about the qualita-
tive research in which they could take part after they
completed the trial procedures planned and if they were
interested. Those volunteers who were interested in get-
ting more information about the qualitative study were
then sent to the qualitative researcher (the first author)
to discuss the details of the qualitative study with them
using the participant information sheets. If they agreed
to take part, they then signed a consent form for the
particular study. Recruitment of participants continued
until the desired sample size was reached [57, 58]. Vol-
unteers in the qualitative study were eligible if they had
been in the clinical trial for at least six months, were
willing to give additional time beyond the time required
for their participation on the trial and had also signed a
consent form for the qualitative study.
Data collection and analysis
To gain an understanding of how the informed consent
process was experienced and interpreted by the volun-
teers in the two HIV clinical trials the first author con-
ducted semi-structured in-depth interviews and focus
group discussions [54]. The interviews and focus groups
were audio-recorded. The first author also carried out
unstructured observation at the research clinics, observ-
ing the research activities and gaining insights on
volunteer-research team interactions and among the vol-
unteers themselves [59]. Data collection was carried out
from January 2012 to Dec 2012. Data analysis was on-
going and inductive throughout the data collection
process, and facilitated in the final stages by using Nvivo
8 qualitative software to manage the coding. Codes were
generated from the first six in-depth interviews and pat-
terns drawn and themes created alongside the data col-
lection process in consultation with the other authors
[60, 61]. The findings were interpreted according to the
themes identified in the data [62].
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Ethics, consent and permissions
This study was reviewed and approved by the Science
and Ethics Committee (SEC) Uganda Virus Research In-
stitute. The study was also approved by the International
Research Ethics Committee of the School of Inter-
national Development at the University of East Anglia,-
Norwich, United kingdom. It was cleared by Uganda
National Council for Science and Technology (UNCST).
Before contacting the respondents, the first author
sought permission for including the two trials in the
qualitative study from the site Principal Investigators. All
interviewees gave their consent by signing a consent
form before they participated in interviews and focus
group discussions. The findings refer to the trials as ei-
ther Trial One or Trial Two to which they were re-
cruited but do not reveal names of volunteers.
Results
Characteristics of volunteers
The volunteers were aged between 19 and 50 years with
the median age of 33 years. There were fourteen female
and nine male volunteers. Two volunteers declined par-
ticipation because they did not have time for the inter-
views and one was removed from the trial because of
the results of diagnostic tests. These were not part of the
twenty three included in the final study. All the volun-
teers knew their HIV sero status since it was a require-
ment for them for taking part in the HIV clinical trials.
The volunteers were all working in their local area, some
in formal employment like security guard but most were
in informal jobs doing business, vehicle mechanics, hair
and beauty salons, drivers and shopkeepers. Two female
volunteers said they were not employed and one of the
male volunteers was a university student. The trial
nurses and mobiliser were the first trial staff contact and
providers of the trial study information for the volun-
teers at the clinic. At every scheduled visit volunteers
had to see a nurse before they moved on to other trial
procedures, and it was at this point that volunteers were
informed about the qualitative study. This paper does
not present other actors’ perspectives.
How volunteers understood study information
An important aspect of informed consent is the discus-
sion of the trial information between the research team
and the volunteers. The discussion of study information
was meant to ensure that the researcher and volunteer
understood what was going to happen during their inter-
action and what procedures, risks and benefits a volun-
teer would go through. As Appelbaum and colleagues
[14] say, ‘The duty of disclosure or duty to inform is the
truly distinguishing and innovative aspect of the in-
formed consent doctrine’[14, 57]. The volunteer percep-
tions on the trial information disclosed to them were
important in pointing to the importance of disclosure of
trial information.
The research teams and scientists proved especially
keen to provide the volunteers with information about
the trial and to ensure that they understood the research
aims [63]. The volunteers on the other hand proved to
be more interested in the practical procedures such as
taking off their blood and urine samples and the state of
their health whether they were still HIV negative or had
an increased number of antibodies for those who were
HIV positive.
Most of the thirteen Trial One volunteers did not see
the vaccine given to them in that trial as an intervention
to prevent HIV but to investigate how their bodies would
react to it including whether it caused them harm.
R4: They told us … that the vaccine we are being
given, they said some will get the real drug and others
will get a placebo; anyway the vaccine is not to
prevent HIV but they want to see how our bodies will
react to the drug.(FGD,Trial One)
One female volunteer reported that ‘they are just
testing this drug on us to see if it cures AIDS, but it
does not prevent it’, adding that she needed to protect
herself from acquiring HIV. This reflects the need for
continuos dialogue between the volunteers and the
research team to deal with misinterpretation of study
information.
All Trial One volunteers knew that the trial involved
randomization, while nonetheless they all hoped they
were on the active and not the placebo arm of the trial.
This seems to reflect their belief about the trial that once
one is given a drug it must be useful to them while also
sometimes doubting the completeness of the informa-
tion the researchers gave them.
R7: That is the truth because the researchers
(abasawo), they hid something from us …Now among
the nine of us, we cannot know whether five got a
placebo or four got the right vaccine. We are looking at
each other because they’ve kept that to themselves [all
laugh], but when they look at us, I think they say
‘Because of what I see, I think what we gave him
works’, because for them, they know.
R6: Even the researchers do not know.
R7: But for them they know the bottle types where they
got the drug to inject us. [All laugh](FGD,Trial One)
When asked what the objectives of the trial were, Trial
Two volunteers commonly suggested that it was to test
what would happen to them if they stopped taking
Cotrimoxazole (Septrin):
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They are researching so that they can see whether we
can stop taking Septrin or we need to continue taking
it. (Female volunteer aged 40, Trial Two)
Despite all ten volunteer interviewees in Trial Two
reporting that they were involved in research on Septrin
and the effects of stopping taking it, only four of them
could directly articulate that there was randomization in
the trial so that some volunteers were on a placebo and
others on the active drug. Two Trial Two volunteers re-
ported in the focus group that the trial was ‘… trying to
find out the effects of stopping taking Septrin but con-
tinuing with ARVs’. The remaining eight volunteers did
not clarify what randomization meant for them person-
ally. One discussant said:
We hoped that if we left that strong Septrin and
remained on the ARVs and the drug they are giving us
we would survive. They also told us that if it doesn’t
work, and you get weak after leaving Septrin and
you’re getting funny effects, you can get back on the old
Septrin. So we got hopeful and said ‘Why don’t we join
– we’ll probably get a cure‘. (FGD Trial Two)
This quote above raises several issues about volunteer
comprehension of study information. First, the volunteer
mentions that they were told they would be put back on
Septrin if they became sick; this was not written in the
trial information sheet however it was part of practice
according to the trial protocol. She also mentioned that
they had been taken off the ‘strong Septrin’, implying that
they may be on some form of drug which is not so strong,
and hopes that by joining the trial that they could be
cured. The volunteers interviewed in this qualitative study
had all been in the trial for at least six months to a year.
Trial Two volunteers had more issues with the kind of
information that they received about the trial than those
in Trial One. While they all first mentioned that the trial
was about Septrin, their discussion of randomization
and any expected trial outcomes were mixed up with ru-
mours from other volunteers. It was not ultimately easy
to tease out which facts about the trial were clear to
them and which ideas about the trial might have devel-
oped, perhaps for example from their own discussion of
the trial, some time after the initial information had
been given to them.
Decision-making by the volunteers
Most Trial Two volunteers decided to join a trial in the
hope that the research would eventually lead to a reduc-
tion in the number of pills they had to take, while Trial
One volunteers hoped that it would protect them from
HIV infection. All volunteers described their participa-
tion in the trial as voluntary. However, they also
described seeking advice from someone they trusted
such as a parent, counsellor or respected community
leader before agreeing to take part.
Although the volunteers had made the decision to join
a trial, some reported later difficulty in keeping to their
decision and continuing in the trial. Trial One volun-
teers reported being discussed in the community, where
it was believed that they had joined a clinical study be-
cause they were infected with HIV. There was stigma at-
tached to attending the research clinic in one of the
study areas because the community believed that since
the MRC conducts HIV and AIDS-related research all
volunteers must be HIV positive. Thus communities still
evoke stigma despite having lived with HIV and AIDS in
Uganda for over two decades [36]. The other difficulty
faced by Trial One volunteers both before and after de-
ciding to participate were fears raised by the rumours
about what others said would happen to them:
Before making the decision we talked about this
research with our friends … and got different feedback,
such as ‘They are going to vaccinate you and you don’t
know what will happen to you in ten or twenty years’:
‘You might grow a lot of hair like monkeys’ [all laugh]
or ‘You will die a slow death’ … It was hard, and we
actually had to think hard before volunteering.
(Volunteer FGD, Trial One)
The volunteers in Trial One were anxious at the start
of the trial, several wondering why the research team
were not taking part in it themselves. Volunteers in the
focus group reported their need for reassurance from
the researchers that the potential harm discussed in the
community would not happen to them. Both trials’ re-
search teams maintained continuous dialogue with the
volunteers to help allay such anxieties.
Some volunteers’ decisions, particularly about Trial
One, were delayed because of having to inform their
spouses, as encouraged by the researchers, and some
spouses did not support their joining the research and
even stigmatized them for it:
My husband would ask me how things had been [at
the clinic] and he would tell me why [the researchers]
do not try those vaccines on animals … sometimes I
got the signs that they had told us about, some
feverishness and feeling cold … Every time I felt a bit
sick he would tell me that I would die in a few days.
(Female volunteer, Trial One FGD)
While some volunteers faced challenges when deciding
whether to join a trial, others did not, either because
they had support from someone such as a parent or be-
cause they were independent in making their decisions,
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as was more common among the men. Gender norms in
this community required that married women made im-
portant decisions after informing and sometimes after
getting permission from their spouse; this was an issue
reported more by Trial One volunteers because enrolling
in the trial required their spouses to be tested for HIV.
Both male and female volunteers in Trial Two were
more independent in their decision to join the trial be-
cause they felt that it was up to them to help to find a
solution to HIV-infection, which was already a challenge
in their lives, and with no trial requirement of HIV test-
ing for their partners.
Deciding to remain in the trial meant that some vol-
unteers had to continuously make decisions, such as
whether to refrain from sexual relationships:
You may admire someone and want to have sex with
them, but because you are taking part in research you
decide to wait until you are done with the research.
(Male volunteer aged 24, Trial One)
Thus individual decision-making patterns differed for
each volunteer according to their social context. The ru-
mours of their being infected with HIV in the trials
made it hard for some of those seeking good health to
decide to take part.
Who influences the decision to participate in research?
Female volunteers confided mainly in their parents be-
fore deciding to join the trial. However, most of the Trial
One male volunteers did not consult anyone, and the
few who did asked the advice of friends or elder siblings.
Some married male volunteers informed their partners
of trial details including expected duration of the trial to
avoid conflict especially because after the initial enrol-
ment they still had to come to the clinic for follow up
visits:
… this depends on you as an individual, but you need
to inform your partner because if you do not tell them
[what happens at the clinic] and yet I usually go home
with leaflets with the MRC information … It might
give her the idea that you’re probably HIV positive
and you haven’t told her. (Male volunteer aged 31,
Trial One)
This comment reflects the type of community stigma
that is attached to volunteering for research. In this soci-
ety, men are not obliged to consult anyone before mak-
ing their decisions but, as seen here, the issue of HIV
and AIDS may raise questions in some relationships.
Many Trial Two volunteers made their decision to
join the trial alone, because they are living with HIV
infection:
I did not seek [my husband’s] advice before I joined the
trial. When l heard what they told me about the
research, I decided on my own to join. My husband
learnt about it later. (Female volunteer aged 25,
Trial Two)
One female volunteer did not disclose her trial partici-
pation to anyone, including her sexual partner at the
time:
I made my own decision. Although I live with a man
he does not know I’m taking part in a trial. (Female
volunteer aged 40, Trial Two)
The volunteers’ privacy was important to them even
though the informed consent process might involve dis-
cussion between family members, the volunteer and
other actors in the research process.
As many volunteers often referred to consulting im-
portant others in their lives before making their final de-
cision to join a trial, if they were to keep in the trial for
the whole duration of the research, researchers should
take the time to find out who these important others in
a volunteer’s social network who might impact on trial
participation [64].
Roles in the informed consent process
Volunteers were asked to describe their roles in the in-
formed consent process to find out how they value their
own and other actors’ contribution. Volunteers often
demonstrated a precise awareness of this:
My role is important because if we don’t enrol then
who will they conduct the research on? Will they do it
on animals? So that all shows that the research team
has to handle us well. (Female volunteer aged 26,
Trial Two).
Another volunteer explained her involvement as a way
to responsibly encourage other people to join research:
My main responsibility is to avoid getting HIV and to
discuss information that l have with other people …
after this experience when I meet people and there is
research being done, I encourage them to join. (Female
volunteer aged 30, Trial One)
The volunteers said that their own role was to keep
their appointments, and once at the research clinic, to
follow what was planned for that visit. A volunteer de-
scribed a typical follow- up visit day:
When I arrive I give in my card, they write my name
and then I wait for about ten minutes. Then I go to see
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the doctor; from there I come back and they take my
blood, then they reimburse my transport costs, then I
get the drugs and I leave. (Female volunteer aged 50,
Trial Two)
All the other respondents including research teams,
ethics committee members and community advisors rep-
resented the volunteer as central to the informed con-
sent process.
Reasons for participating in an HIV clinical trial
The reasons volunteers gave for joining the clinical trial
were related to their experiences with HIV and AIDS.
The effects of HIV or present HIV-infected state led
them to participate. The volunteers in both studies ex-
pected that a solution to the HIV problem would be
found in the future. Trial One volunteers hoped that
they would be protected from acquiring HIV infection
while the Trial Two volunteers expected to lead a better
quality of life as a result of the trials. These two issues
point to forms of therapeutic misconception in each case
with Trial One volunteers hoping participation would
lead to protection from acquiring HIV and for Trial Two
volunteers hoping to gain improved quality of life.
There were also marked differences between the two
groups of volunteers’ reasons for continuing to take part
in trials. Whereas Trial One volunteers were concerned
with avoiding catching HIV, Trial Two volunteers sought
strategies for helping them cope with their HIV-positive
status, in line with their cultural obligations, beliefs and
expectations of the trial with a few reporting an additional
reason as being to help others benefit from the research
finding that fewer people would be taking too many drugs.
All Trial One volunteers reported their main reason for
continuing trial participation was their desire to protect
themselves from catching HIV because of the study infor-
mation on consistent condom use that they were
reminded about during the clinic follow up visits. When
asked how being in a research trial could help with this,
the majority said that the research team’s HIV-prevention
messages such as ‘consistent use of condoms for every
sexual act’ were constant reminders that the intervention
vaccine did not protect them from acquiring HIV.
The typical first response of Trial Two volunteers
about why they stayed in the clinical trial was their ex-
pectation of medical advances from the trial:
I expect we will eventually get a drug that will cure us,
and I will get cured myself. (Female volunteer aged 40,
Trial Two)
Two male volunteers in Trial Two hoped to each have
a son, in the future. One of these men was happy to re-
port that his pregnant wife was still HIV-negative:
I’m still lucky; my wife is HIV-negative … now she is
pregnant, about to have a second child. And if God
helps me and it is a boy then I will be one of the luckiest.
(Male volunteer aged 39, Trial Two)
The other male volunteer also hoped one day to have
another child:
I have been hoping that in the near future I will be
fine and be able to get a woman and have a child,
probably an heir, because currently I only have one
child. (Male volunteer aged 50, Trial Two)
While this volunteer already had a wife and one child,
after many years without another child the beliefs and
values of this society underpinned his desire to acquire
another wife and probably another child [65–67] . These
two examples show the type and degree of emotional
and psychological stress that people living with HIV may
feel while trying to cope with HIV infection.
Feelings about the time required for the trial procedures
Taking part in the trial procedures may present the vol-
unteers with many difficulties. Many in Trial One re-
ported how challenging they found the length of time
they needed to spend at the research clinics.
This was not the case for most Trial Two volunteers,
some of whom favourably compared their shorter waits
to collecting their ARVs in the research clinics than from
service institutions.
A Trial Two volunteer explained the importance of
the shorter time spent at the research clinic:There is
such a big difference between institution D [a service in-
stitution] and this trial clinic. In D you may wait from
morning to 2 pm for your turn to be seen by the
counsellor or clinician – at least here they work fast and
then you can go back and do your work . (Female volun-
teer aged 26, Trial Two)
Trial Two volunteers reported delays at the phar-
macy when they attended the clinic. Observing the
pharmacy, it was apparent that one research team
member usually worked alone providing refills and
dealing with prescriptions for all research volunteers.
This was a slow process and a source of some discom-
fort for some volunteers.
Trial One volunteers repeatedly related the acute
problem of the longer time spent at the clinic, to their
job commitments; identifying what they gave up to at-
tend, mainly in monetary terms. A focus group discus-
sion quote highlights such concerns:
I think there are too few doctors. Although we agreed
to be volunteers we have other things we want to go
and do. I think the issue of time can actually cause
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people to drop out, even if they volunteered willingly.
(FGD Trial One)
Despite volunteers’ complaints about lost time, the
research team had to take the volunteers through the
planned procedures on each scheduled clinic visit.
This could indirectly affect the way research proce-
dures are managed by the research team, because
they had to work very fast in response to the volun-
teers’ demands.
The Trial One volunteers in this study were not
often sick, and it was not easy to handle their time
because even on arriving for their interviews for this
study they always began by announcing how little
time they had, which reflected their concerns about
time taken up by the trial. A Trial One volunteer sug-
gested that the research team should separate the vol-
unteers who require health care from those invited
for scheduled research visits to minimise time spent
at the clinic.
Since time was seen to be critical to the volunteers in
Trial One, the research team members were interviewed
about their views on the time taken by the research pro-
cedures. All team and SEC members reported having
enough time to share trial information at the start of a
trial as very important when conducting a trial to enable
volunteers to ask questions and have them answered by
the research team, to help them understand the study
they are involved in and its rationale.
The research team and SEC generally reported that
spending time on explanatory procedures, especially at
the start of a trial, is essential. This view was however
challenged by my finding that procedures such as blood
and urine sample collection were reported spontan-
eously by volunteers while other procedures were less
significant to them, so spending much time on explain-
ing such procedures was not welcomed by them.
The volunteers offered some suggestions for reducing
time spent at the clinic, including dividing the research
team into two groups, one to take care of sick volunteers
and the other to handle research volunteers’ scheduled
appointments.
Reasons why volunteers drop out of trials
Volunteers were interviewed about reasons why some
dropped out of research trials. Their reasons included
losing interest in the trial, not having time for follow-up
visits, and difficulties finding money for transport to the
clinic. While the research team refunded transport costs
after a scheduled visit, some volunteers could not find
enough money to attend the clinic and ended up drop-
ping out of the trial. See Table 1 below for the summary
comparison of responses from the trial volunteers in the
two trials.
Volunteer experiences during the informed consent process
When describing the study procedures in the informed
consent process, in their first interviews with the first au-
thor, the volunteers detailed what happened to them from
first walking into the research clinic, and the information
the research team provided. Explaining what procedures
volunteers found important during the three monthly
follow–up clinic visits, most commented that nothing
about the trial procedures they underwent had changed. It
may have been the case that nothing had changed, these re-
sponses may partly have been because the second time they
met the interviewer (first author), she was no longer a
stranger to the research so they expected her to know what
was going on or because the procedures had become ‘usual’
to them and therefore did not require further reporting.
When interviewed about specific procedures the vol-
unteers all mentioned that research teams collected
blood and urine samples from them, easily describing
the different procedures they went through and knew
what to expect at their scheduled visits. This reflects the
trust they had in the research team. Volunteers de-
scribed such procedures subsequently as “usual proce-
dures” during their second and third interviews, while
always reporting that they had given a blood and urine
sample during the follow up clinic visits:
They were the usual [procedures]; of course when I
went they took my urine sample and a blood sample.
(Female volunteer aged 25, Trial One)
Another female reported that she had been repri-
manded by research team members because she had
been sick and had not come to the clinic for treatment,
as required of her as a volunteer:
I told them what I had gone through and that I had
been sick but had not reported it and they rebuked me
because they had told us to come when we are sick.
They took a blood sample and then they gave me more
Septrin. (Female volunteer aged 40, Trial Two)
The regular clinical procedures reported here were ex-
pected by the volunteers. However, as seen in the sec-
ond quote above volunteers may not always adhere to
everything required of them as specified in the informa-
tion they had discussed earlier with the research team.
Significance of signing and thumb printing the consent forms
Volunteers were asked what significance they gave to
signing the consent forms and how they would gauge
whether someone had understood the trial information
that the research team provided. All volunteers reported
that it was very important that they sign or thumbprint
the consent forms and that informed consent must be
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documented; most said that signing the consent forms
showed a volunteer agreed to participate in a trial with-
out coercion.
Most volunteers discussed signing or thumb printing
the consent forms matter-of-factly, as a usual procedure,
perhaps indicating that they were used to the way re-
search studies are run. The volunteers reported signing a
consent form as part of ensuring their formal agreement
to join a study. The volunteers in these two trials stated
that there was no alternative to signing or thumb print-
ing the consent forms in research:
Even if I’ve agreed to participate, you cannot know
[that I have agreed to take part in the trial] until
someone puts it in writing. You know things that you
just talk about are not easy to accept unless you have
put something in place. (Female volunteer aged 30,
Trial Two)
The volunteers reported that signing or thumb print-
ing a document was not a challenge for them, and saw
refusal to sign the consent forms as indicating a poten-
tial volunteer’s lack of interest in a study.
Volunteers able to write were asked what they
thought about the possibility of being asked to provide
a thumbprint on the consent forms, a required practice
in research before enrolling volunteers unable to read
or write. The volunteers felt it was not right to ask
someone who could write to sign with a thumbprint. It
was prestigious for a volunteer to be able to sign the
consent forms, but there was stigma attached to thumb
printing.
A male volunteer mentioned that thumbprints may be
used in banks and elsewhere, but asking a research vol-
unteer to thumbprint the consent forms when able to
write their name was not acceptable. To some volun-
teers however, it did not matter whether they signed or
thumb printed the form.
Signing the consent forms was a research require-
ment which the volunteers accepted without question.
The main reason most volunteers gave for the neces-
sity of signing was to show that they had not been
coerced; they did not mention anything related to
study content such as the trial’s objectives and proce-
dures as presented by research teams at the informa-
tion sessions.
Most volunteers felt that it did not matter whether
one signed or thumb printed; what was important was
being able to understand the information given by the
research team:
We need to know that both a person who has
understood and one who has not understood can sign.
(Female volunteer aged 31, Trial One)
Volunteers’ suggestions for the informed consent process
The volunteers made several suggestions about improv-
ing activities that took place during the research, all of
which related to the informed consent process including:
gauging their understanding after being in a research
trial for a while, as testing for comprehension of study
information soon after providing it might only have
shown that they could recall it superficially:
Questions should not be asked immediately, because
sometimes we are asked questions about what we have
just been told; the brain is still recalling what you read
to me some ten minutes ago. (Male volunteer aged 27,
Trial One)
The volunteers also suggested that all study informa-
tion should be simple and clear:
When we are given information it does not tell us
definitely what will happen to the baby [if a volunteer
gets pregnant] – they always say the baby ‘might have
a problem’. Even the people who give the information
are not definite. (Male volunteer aged 27, Trial One)
The consent document for one trial stated; ‘We do not
know what effect the vaccine would have on an unborn
child if given to a pregnant woman. If you become preg-
nant during the study, you will not get any more vacci-
nations’ (ICD). While the research team may have easily
understood this sentence, the volunteer’s concern was
that it left room for the volunteer to decide whether to
get pregnant or not.
They also suggested that the research teams should
hold more than a single information session to ensure
that volunteers understand the trial objectives.
Volunteers suggested that the research teams should
devise an adult literacy programme to support volun-
teers who cannot write their names, during long-term
trials so that volunteers unable to write their names at
the start of a trial would be able to do so by the end, as
a useful benefit for volunteers. This suggestion high-
lights the community stigma attached to volunteers un-
able to sign his/her name on the consent forms. The
suggestion persisted through later interviews and the
focus group discussions despite all volunteers having
noted that understanding the study information has
nothing to do with ability to sign consent forms.
Other suggestions to improve the informed consent
process were personal, such as requesting for more
money for transport to the clinic because travel costs
fluctuate. A few female volunteers suggested that re-
search should not include females aged 25 years or
younger, who still needed to have children and might
not wait for a long time of the trial before they became
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pregnant. Young wives were expected by their husbands
to get pregnant when they have been married. Another
suggestion related to reproductive health was that clin-
ical trials should only enrol non-sexually active women.
Both suggestions relate to the sociocultural norms in
this community; once married, a woman is expected to
produce children as soon as possible [67]. A male volun-
teer suggested that female volunteers should be given
hormonal family planning methods such as contracep-
tive injections to avoid pregnancy during a trial.
A focus group discussion with the volunteers sug-
gested to the importance of informing them about all
research activities taking place at the research clinic.
For example, they suggested that the research teams
should explain when there were multiple research
projects going on simultaneously to help volunteers
understand that sometimes they would have to wait
for a while before being called in to see research
team members who were carrying out the scheduled
trial procedures.
Discussion
The informed consent process in this study focussed on
the volunteer perceptions and experiences of the informed
consent process, which underlined that the interactions
and communications between volunteers and research
team vitally supported understandings of the consent
process similar to what was found in Kenya [64]. Here we
discuss volunteer understanding of study information, de-
cision making patterns, their roles and experiences during
the informed consent process and their views on signing
and thumb printing consent forms.
While the researchers may spend much time presenting
the volunteers with the trial overview information such as
study design, trial key messages, planned interviews and
clinical examinations to be conducted, this study has
found that at the start of a trial volunteers may not con-
sider all of this information important. The volunteers
were keen to report the procedures that involved giving
blood and urine samples at clinic visits. Volunteers re-
ported these more readily than general information
provided about trial objectives. It may be more appro-
priate to discuss such information piecemeal and in
stages as the volunteer progresses through the trial.
The volunteers again alluded particularly to respect-
related issues when discussing their comprehension of
the study information. They suggested that a non-
literate individual was able to understand this informa-
tion as well as a literate individual when it was discussed
in their own language. Therefore whether a volunteer
signed their name or they were only able to make a
mark using their thumbprint on the consent forms, they
did not see this as reflecting their ability or failure to
comprehend study information.
Research ethics guidelines emphasize that non-literate
volunteers must have literate witnesses present when
they receive the study information and when signing the
form consenting to take part in the research [2, 68, 69].
Some volunteers saw the signed consent forms as legal
documents binding the researcher and the volunteer in a
research relationship for the trial’s duration. If volun-
teers view the consent forms as legal documents, they
may not ask questions pertaining to their participation
in research since they would assume that they are bound
by signing the document. This may imply inequality be-
tween research volunteer and researcher which may not
foster continued collaboration. Only two volunteers re-
ported having referred back to their signed consent
forms. When a few of the volunteers reported in this
study referring to the trial information sheet, it under-
pins the importance of having an on-going informed
consent process as the researcher and volunteer interact
in order to ensure true informed consent [49].
Decisions on whether to join a trial and continue par-
ticipation can be influenced by the individual volunteer’s
values and beliefs, their trust in the research team, the
power dynamics during the interactions between the vol-
unteer, relatives and research team. A study by Kingori
reported that many participants made the decision to
join research even before they were given study details
[70]. Social cultural factors in their community also
played a role in how they made decisions to join or con-
tinue in a trial, gender-related issues were prominent, es-
pecially for women who in most relationships made
reproductive health decisions with permission of or in
consultation with their spouses [66, 71].
The volunteers based their decision to take part in the
trials on their trust that the study information provided
by the research team and the trial procedures they
would undergo would not cause them harm. This shows
the trust built between the volunteer and the research
team while interacting with each other as a factor that
may lead to the volunteer’s continued participation in a
clinical trial which trust has also been noted in neigh-
bouring Kenya [20, 64].
Volunteers’ main reason for taking part in the clinical
trials related to past and present experiences with HIV
and AIDS, some volunteers having experienced deaths
of close family members and friends and some were liv-
ing with HIV. Some volunteers gave altruism as one of
their reasons for taking part in research, yet all the vol-
unteers named routine health checks as the main benefit
from being involved in research.
In this study, the standardised national research ethics
guidelines were particularly emphasised as important by
the ethics committee and the senior scientists conduct-
ing the trials, who had to ensure that the procedures re-
search volunteers went through were aligned to what the
Ssali et al. BMC Medical Ethics  (2015) 16:86 Page 11 of 14
guidelines stipulate. We found that the nature of the
trial and the research setting may contribute to the re-
cruitment and retention outcome from the informed
consent process which result is similar to the findings of
Molyneux and colleagues, for parents who consented to
their children joining a vaccine trial [48].
We found in our research that in the prevention trial
where the volunteers were not ill, they could easily de-
cline to join the research if they found that they were to
spend a lot of time for which they had other priorities.
Those volunteers in a treatment trial, were unlikely to
press hard to limit the time they needed to spend at the
clinic because they believed that good health was
dependent on taking drugs and obtaining good health
care from such a research clinic.
The volunteers’ discussion of informed consent had
nothing to do with the technical expectations laid down
in the human research ethics guidelines. They showed
little awareness of principles of documented research,
yet they had been provided with specific information
about the trials that they had joined, and with copies of
the consent forms they had signed when being screened
and enrolled. While it could be argued that this was a
procedure enacted by the research team to accord vol-
unteers respect by asking for their consent individually,
it is also a research ethics requirement while conducting
research [2, 6]. Beyond the signed consent forms by the
volunteer and the research team member, there was no
documentation to show how the on-going interactions
between the research team and the volunteers were
managed to protect the volunteer.
Volunteers may continue to participate in research
because of their personal aspirations which may not neces-
sarily relate to the objectives of a trial. Volunteers’ expecta-
tions related to the individual; how they would be
protected from foreseeable risks relating to the trial and
might benefit from taking part in the trial [72]. A male vol-
unteer who had felt more constrained from having sex with
strangers noted that taking part in the research enforced
positive behaviour such as consistent condom use with
every sexual partner and saw this as a benefit for him.
Although the participant information sheet indicated
that the volunteer was free to take part in a trial and to
withdraw at any time, it also spelt out how trial
protocol-based procedures needed to be followed by the
volunteer, to do what was required of them by the re-
search team after agreeing to take part. The findings
show that volunteers may not give equal attention to all
issues the research team emphasized, such as reporting
to the clinic whenever they were unwell when other op-
tions such as getting treatment from a nearby drug shop
might have been available to them. All such factors
meant that volunteers might not always adhere to the re-
search team’s expectations.
The research team and volunteers did not always,
therefore, attach the same importance to aspects of the
informed consent process. This shows not only that the
volunteer is dependent on the research team but also
that the research team is dependent on the volunteers’
input to the informed consent process, in terms of con-
senting to adhere to the trial procedures.
The volunteers’ opinions about decision-making and
consenting to take part in clinical trials demonstrated
their active and sometimes changing involvement in the
informed consent process and their ability to reflect and
comment on what they observed during the research
process.
Volunteers’ suggestions for the informed consent
process showed their interest in what would happen to
them during research and also that significant others
were critical in their decision to join a trial [64]. They
also highlighted that study information needed to be
presented clearly to overcome misinterpretation of key
study messages and procedures by the volunteers. They
also emphasised that volunteer comprehension of this
information was not simply and only linked to literacy,-
but may be affected by other factors such as participants’
ill health or wellbeing [73].
Study limitations
The main limitation was that the purposive selection of
volunteers may have led to some bias in who was invited
to join the qualitative trial. The study was conducted at
the clinic setting which may have influenced the volun-
teers’ freedom to respond to the research questions since
clinical procedures were being conducted at the clinic.
The main researcher could not observe volunteers-
clinic team interactions within the clinic room which
meant that she had to rely on reported information and
observations outside the clinic rooms.
Conclusion
Although the regulatory guidelines provide a description
of what the informed consent process should involve for
individual participation, in practice the beliefs, values,
trust and power dynamics during clinical trial implemen-
tation were seen to influence the consent process in which
the volunteers and the research team interacted with each
other and with their wider social networks. The sugges-
tions by volunteers for improving clarity and their com-
prehension of trial information during the informed
consent process require responses from the research com-
munity particularly as these highlighted how scientific
terms used may not be well-understood after translation
into lay terms. Volunteers’ comprehension of key informa-
tion in trials should not be assessed immediately after
information-giving because what they convey may be lit-
eral recall rather than necessarily a full understanding.
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The informed consent process is not only about formal
enactment of regulations as isolated events, but also de-
pends on the continuing interactions between the research
team, the research volunteers and their communities
throughout the trial.
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